ストックスクリーナーアプリを入手
4.76
3.84%
-0.19
アフターアワーズ：
4.53
-0.23
-4.83%
前日終値:
$4.95
開ける：
$4.92
24時間の取引高:
861.51K
Relative Volume:
1.90
時価総額：
$268.61M
収益：
-
当期純損益:
$-72.89M
株価収益率:
-1.9669
EPS:
-2.42
ネットキャッシュフロー:
$-68.47M
1週間 パフォーマンス:
+21.43%
1か月 パフォーマンス:
-7.03%
6か月 パフォーマンス:
-54.19%
1年 パフォーマンス:
-47.17%
1日の値動き範囲:
$4.54
$4.92
1週間の範囲:
$3.83
$4.98
52週間の値動き範囲:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
ATXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
4.76 | 221.22M | 0 | -72.89M | -68.47M | -2.42 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-29 | 開始されました | TD Cowen | Buy |
| 2023-03-28 | 開始されました | Evercore ISI | Outperform |
Astria Therapeutics Inc (ATXS) 最新ニュース
Deutsche Bank AG Buys 13,986 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference - Business Wire
Janus Henderson Group PLC Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficien - GuruFocus
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop - Business Wire
Northern Trust Corp Has $4.10 Million Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics to Present at Upcoming Eastern Allergy Confe - GuruFocus
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference | ATXS Stock News - GuruFocus
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference - Business Wire
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $30.00 - Defense World
Price T Rowe Associates Inc. MD Buys 2,878 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Cantor Fitzgerald Analysts Lower Earnings Estimates for ATXS - Defense World
Wedbush Lowers Earnings Estimates for Astria Therapeutics - Defense World
Q2 EPS Estimate for Astria Therapeutics Lowered by Analyst - Defense World
Astria Therapeutics’ (ATXS) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
FMR LLC Reduces Holdings in Astria Therapeutics Inc - GuruFocus
(ATXS) Technical Data - news.stocktradersdaily.com
Astria Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Astria Therapeutics Reports Increased Loss Amid Rising R&D Costs - TipRanks
Analyst Reiterates Overweight Rating for ATXS with Stable Price Target | ATXS Stock News - GuruFocus
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation - Yahoo Finance
Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update | ATXS Stock News - GuruFocus
Astria Therapeutics (ATXS) Advances Navenibart as Groundbreaking HAE Therapy | ATXS Stock News - GuruFocus
Astria Therapeutics (ATXS) Sees Price Target Adjustment Amid Ong - GuruFocus
Astria Therapeutics price target lowered to $25 from $26 at Citizens JMP - TipRanks
Astria Therapeutics Q1 Operating Expenses USD 36.995 Million - marketscreener.com
Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Business Wire
Astria Therapeutics, Inc. SEC 10-Q Report - TradingView
Tower Research Capital LLC TRC Purchases 2,766 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Is Astria Therapeutics, Inc. (ATXS) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Wells Fargo & Company MN Acquires 7,563 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Astria Therapeutics Inc (ATXS)’s Day in Review: Closing at 4.42, Up by 1.14 - DWinneX
Transcript : Astria Therapeutics, Inc. Presents at The Citizens JMP Life Sciences Conference 2025, May-07-2025 10 - marketscreener.com
Astria Therapeutics at Citizens JMP: Advancing HAE Treatments By Investing.com - Investing.com India
Astria Therapeutics at Citizens JMP: Advancing HAE Treatments - Investing.com Australia
Raymond James Financial Inc. Buys Shares of 79,044 Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Barclays PLC Boosts Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
(ATXS) Long Term Investment Analysis - news.stocktradersdaily.com
Astria Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Invesco Ltd. Has $161,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATXS Stock News - GuruFocus
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wall Street analysts’ outlook for Astria Therapeutics Inc (ATXS) - Sete News
Financial Metrics Check: Astria Therapeutics Inc (ATXS)’s Ratios for Trailing Twelve Months - DWinneX
Brokers Set Expectations for ATXS FY2025 Earnings - Defense World
Breaking down ATXS’s current quarter earnings estimates - uspostnews.com
Astria Therapeutics Announces Publication of Navenibart Phase 1a - GuruFocus
Astria Therapeutics Inc (ATXS) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):